Erectile Dysfunction Drugs Market
Erectile Dysfunction Drugs Market Forecasts to 2030 - Global Analysis By Drug Type (Viagra (Sildenafil Citrate), Avanafil (Stendra/Spedra) and Other Drug Types), Route of Administration (Oral Medications, Topical Medications and Injections), Distribution Channel and By Geography
|
Years Covered |
2021-2030 |
|
Estimated Year Value (2023) |
US $2.83 BN |
|
Projected Year Value (2030) |
US $5.11 BN |
|
CAGR (2023 - 2030) |
8.8% |
|
Regions Covered |
North America, Europe, Asia Pacific, South America, and Middle East & Africa |
|
Countries Covered |
US, Canada, Mexico, Germany, UK, Italy, France, Spain, Japan, China, India, Australia, New Zealand, South Korea, Rest of Asia Pacific, South America, Argentina, Brazil, Chile, Middle East & Africa, Saudi Arabia, UAE, Qatar, and South Africa |
|
Largest Market |
North America |
|
Highest Growing Market |
Asia Pacific |
According to Stratistics MRC, the Global Erectile Dysfunction Drugs Market is accounted for $2.83 billion in 2023 and is expected to reach $5.11 billion by 2030 growing at a CAGR of 8.8% during the forecast period. Erectile dysfunction (ED) drugs are medications designed to treat the inability to achieve or maintain an erection sufficient for sexual intercourse. They work by increasing blood flow to the penis, facilitating an erection when sexually stimulated. Common ED drugs include sildenafil (Viagra), tadalafil (Cialis), and vardenafil (Levitra), which belong to a class of medications called phosphodiesterase type 5 (PDE5) inhibitors. These drugs are typically taken orally and have revolutionized the treatment of ED, offering millions of men a reliable and effective solution to enhance their sexual performance and quality of life.
According to the Clinical Epidemiology and Global Health Journal, Erectile Dysfunction affects more than 150 million men globally, and by 2025, that number is predicted to rise to 322 million. According to the National Institutes of Health (NIH), in 2022, erectile dysfunction (ED) is very common condition in U.S. It affects about 30 million men in the U.S. every year.
Market Dynamics:
Driver:
Growing awareness and acceptance
The growing awareness and acceptance of ED drugs in the erectile dysfunction market signifies the increasing recognition and normalization of ED as a medical condition. As societal attitudes evolve and conversations around sexual health become more open, individuals are more likely to seek treatment for ED. This shift in perception leads to greater acceptance of ED drugs as legitimate solutions, boosting their demand. Additionally, education campaigns and advertising efforts play a crucial role in spreading awareness about available treatment options, further fueling market growth.
Restraint:
Regulatory hurdles
Regulatory hurdles in the erectile dysfunction drug market primarily stem from stringent approval processes and ongoing monitoring by health authorities. These hurdles include rigorous clinical trials to establish safety and efficacy, as well as compliance with labeling and advertising regulations. Additionally, concerns over potential side effects and interactions with other medications contribute to the regulatory complexity. Market entry may also be delayed by patent protections and intellectual property disputes. Navigating these regulatory hurdles demands substantial resources and expertise, which can restrain competition and innovation in the ED drug market.
Opportunity:
Innovation in drug development
The innovation in drug development within the erectile dysfunction market presents a promising opportunity for both pharmaceutical companies and patients. With advancements in understanding the underlying causes of ED, such as vascular issues, neurological disorders, and hormonal imbalances, researchers can target novel pathways for drug interventions. This innovation could lead to more effective and safer treatment options, potentially with fewer side effects compared to current medications like Viagra and Cialis. Furthermore, breakthroughs in personalized medicine may enable tailored treatments based on individual patient characteristics, enhancing efficacy and patient satisfaction.
Threat:
Patent expiry
The patent expiry threat in the Erectile Dysfunction drugs market refers to the looming loss of exclusivity for major medications like Viagra, Cialis, and Levitra. As these patents expire, generic versions can enter the market, leading to intense competition and price erosion for the original brands. This could significantly impact revenue streams for pharmaceutical companies that have held exclusive rights to these drugs. Moreover, generic alternatives often come at lower prices, enticing consumers away from branded products. This scenario poses a challenge for companies to maintain market share and profitability in the face of increased competition.
Covid-19 Impact:
The COVID-19 pandemic had a significant impact on the erectile dysfunction (ED) drug market. With restrictions on movement and healthcare priorities shifting towards managing the pandemic, the demand for ED drugs saw fluctuations. While initial lockdowns led to a decrease in doctor visits and prescriptions, there was a subsequent rise in demand as restrictions eased and telemedicine became more prevalent. Due to house restrictions, there was a substantial growth of intimate activities among newlywed couples and others, which consequently led to growth of several things related to intercourse including ED drugs. Economic uncertainties also influenced consumer spending on non-essential medications like ED drugs.
The viagra (sildenafil citrate) segment is expected to be the largest during the forecast period
The growth of the Viagra (Sildenafil Citrate) segment in the ED drug market can be attributed to several factors. Viagra was one of the pioneering drugs in ED treatment, establishing a strong brand presence and trust among consumers. Its efficacy in treating ED is well-established, leading to widespread adoption by physicians and patients alike. The availability of generic versions of Sildenafil Citrate has increased affordability and accessibility, further fueling market growth. Moreover, continuous research and development efforts have resulted in innovative formulations and delivery methods, expanding the market reach. Furthermore, increasing awareness about ED and the destigmatization of seeking treatment have contributed to the overall expansion of the ED drug market, with Viagra leading the charge.
The topical medications segment is expected to have the highest CAGR during the forecast period
The growth in the topical medication segment can be attributed to the convenience and discretion offered by topical formulations, appealing to consumers seeking non-invasive treatment options. Advancements in formulation technology have improved the efficacy and absorption rates of topical medications, enhancing their effectiveness. The growing awareness and acceptance of topical treatments among both patients and healthcare providers have fuelled market demand. Additionally, the preference for localized treatment with fewer systemic side effects has bolstered the adoption of topical medications, contributing to the segment's sustained expansion.
Region with largest share:
The North American region has experienced significant growth in the erectile dysfunction drug market due to increasing awareness about ED and its growing treatment options. Advancements in medical technology have led to the development of more effective and safer ED drugs, boosting consumer confidence and uptake. Additionally, the aging population in North America, coupled with lifestyle factors such as stress and sedentary habits, has contributed to the rise in ED cases, thus driving the demand for treatment. Robust healthcare infrastructure and favourable reimbursement policies in the region have facilitated access to ED drugs, further fuelling market growth.
Region with highest CAGR:
The Asia-Pacific region has witnessed a notable surge due to several factors. Increasing awareness about sexual health, the rising incidence of lifestyle-related disorders, and expanding access to healthcare services are key drivers. Furthermore, cultural shifts towards more open discussions about sexual health have reduced stigma, encouraging individuals to seek treatment. Furthermore, the availability of innovative treatment options has fuelled market growth. With a large population base and improving healthcare infrastructure, the Asia-Pacific region presents significant opportunities for further expansion in the erectile dysfunction drug market.
Key players in the market
Some of the key players in Erectile Dysfunction Drugs market include Abbott Laboratories, Allergan plc, Apricus Biosciences, Inc., Bayer AG, Cristália Produtos Químicos Farmacêuticos Ltda., Dong-A Pharmaceutical Co., Ltd., Eli Lilly and Company, Endo International plc, Futura Medical plc, Ion Channel Innovations, LLC, Johnson & Johnson, Meda Pharmaceuticals Inc., Metuchen Pharmaceuticals, LLC, Pfizer Inc., Regent Pacific Group Limited, Sandoz International GmbH, Sinil Pharmaceutical Co., Ltd., SK Chemicals Co., Ltd., Teva Pharmaceutical Industries Ltd. and VIVUS, Inc.
Key Developments:
In March 2024, Johnson & Johnson’s JNJ wholly-owned subsidiary, Johnson & Johnson MedTech, recently announced its partnership with Nvidia to accelerate secure, real-time analysis of surgical data using artificial intelligence (AI). The two businesses collaborated to enable more global availability of AI algorithms and real-time analytical access. Their goal is to have an impact on surgical decision-making, teamwork, and education in all linked operating rooms (ORs).
In January 2024, Glenmark said it has partnered with Pfizer to launch abrocitinib in India used for treatment of moderate-to-severe atopic dermatitis (AD). Glenmark and Pfizer will co-market abrocitinib in India under the brand names JABRYUS and CIBINQO. Developed by Pfizer, abrocitinib has received marketing authorization for abrocitinib in adults with moderate-to-severe atopic dermatitis from the Central Drugs Standard Control Organization (CDSCO).
Drug Types Covered:
• Viagra (Sildenafil Citrate)
• Avanafil (Stendra/Spedra)
• Cialis (Tadalafil)
• Helleva (Lodenafil Carbonate)
• Levitra/Staxyn (Vardenafil)
• Mvix (Mirodenafil)
• Vitaros (Alprostadil)
• Zydena (Udenafil)
• Other Drug Types
Route of Administrations Covered:
• Oral Medications
• Topical Medications
• Injections
Distribution Channels Covered:
• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies
Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Emerging Markets
3.7 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Erectile Dysfunction Drugs Market, By Drug Type
5.1 Introduction
5.2 Viagra (Sildenafil Citrate)
5.3 Avanafil (Stendra/Spedra)
5.4 Cialis (Tadalafil)
5.5 Helleva (Lodenafil Carbonate)
5.6 Levitra/Staxyn (Vardenafil)
5.7 Mvix (Mirodenafil)
5.8 Vitaros (Alprostadil)
5.9 Zydena (Udenafil)
5.10 Other Drug Types
6 Global Erectile Dysfunction Drugs Market, By Route of Administration
6.1 Introduction
6.2 Oral Medications
6.3 Topical Medications
6.4 Injections
7 Global Erectile Dysfunction Drugs Market, By Distribution Channel
7.1 Introduction
7.2 Hospital Pharmacies
7.3 Online Pharmacies
7.4 Retail Pharmacies
8 Global Erectile Dysfunction Drugs Market, By Geography
8.1 Introduction
8.2 North America
8.2.1 US
8.2.2 Canada
8.2.3 Mexico
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 Italy
8.3.4 France
8.3.5 Spain
8.3.6 Rest of Europe
8.4 Asia Pacific
8.4.1 Japan
8.4.2 China
8.4.3 India
8.4.4 Australia
8.4.5 New Zealand
8.4.6 South Korea
8.4.7 Rest of Asia Pacific
8.5 South America
8.5.1 Argentina
8.5.2 Brazil
8.5.3 Chile
8.5.4 Rest of South America
8.6 Middle East & Africa
8.6.1 Saudi Arabia
8.6.2 UAE
8.6.3 Qatar
8.6.4 South Africa
8.6.5 Rest of Middle East & Africa
9 Key Developments
9.1 Agreements, Partnerships, Collaborations and Joint Ventures
9.2 Acquisitions & Mergers
9.3 New Product Launch
9.4 Expansions
9.5 Other Key Strategies
10 Company Profiling
10.1 Abbott Laboratories
10.2 Allergan plc
10.3 Apricus Biosciences, Inc.
10.4 Bayer AG
10.5 Cristália Produtos Químicos Farmacêuticos Ltda.
10.6 Dong-A Pharmaceutical Co., Ltd.
10.7 Eli Lilly and Company
10.8 Endo International plc
10.9 Futura Medical plc
10.10 Ion Channel Innovations, LLC
10.11 Johnson & Johnson
10.12 Meda Pharmaceuticals Inc.
10.13 Metuchen Pharmaceuticals, LLC
10.14 Pfizer Inc.
10.15 Regent Pacific Group Limited
10.16 Sandoz International GmbH
10.17 Sinil Pharmaceutical Co., Ltd.
10.18 SK Chemicals Co., Ltd.
10.19 Teva Pharmaceutical Industries Ltd.
10.20 VIVUS, Inc.
List of Tables
1 Global Erectile Dysfunction Drugs Market Outlook, By Region (2021-2030) ($MN)
2 Global Erectile Dysfunction Drugs Market Outlook, By Drug Type (2021-2030) ($MN)
3 Global Erectile Dysfunction Drugs Market Outlook, By Viagra (Sildenafil Citrate) (2021-2030) ($MN)
4 Global Erectile Dysfunction Drugs Market Outlook, By Avanafil (Stendra/Spedra) (2021-2030) ($MN)
5 Global Erectile Dysfunction Drugs Market Outlook, By Cialis (Tadalafil) (2021-2030) ($MN)
6 Global Erectile Dysfunction Drugs Market Outlook, By Helleva (Lodenafil Carbonate) (2021-2030) ($MN)
7 Global Erectile Dysfunction Drugs Market Outlook, By Levitra/Staxyn (Vardenafil) (2021-2030) ($MN)
8 Global Erectile Dysfunction Drugs Market Outlook, By Mvix (Mirodenafil) (2021-2030) ($MN)
9 Global Erectile Dysfunction Drugs Market Outlook, By Vitaros (Alprostadil) (2021-2030) ($MN)
10 Global Erectile Dysfunction Drugs Market Outlook, By Zydena (Udenafil) (2021-2030) ($MN)
11 Global Erectile Dysfunction Drugs Market Outlook, By Other Drug Types (2021-2030) ($MN)
12 Global Erectile Dysfunction Drugs Market Outlook, By Route of Administration (2021-2030) ($MN)
13 Global Erectile Dysfunction Drugs Market Outlook, By Oral Medications (2021-2030) ($MN)
14 Global Erectile Dysfunction Drugs Market Outlook, By Topical Medications (2021-2030) ($MN)
15 Global Erectile Dysfunction Drugs Market Outlook, By Injections (2021-2030) ($MN)
16 Global Erectile Dysfunction Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
17 Global Erectile Dysfunction Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
18 Global Erectile Dysfunction Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
19 Global Erectile Dysfunction Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
20 North America Erectile Dysfunction Drugs Market Outlook, By Country (2021-2030) ($MN)
21 North America Erectile Dysfunction Drugs Market Outlook, By Drug Type (2021-2030) ($MN)
22 North America Erectile Dysfunction Drugs Market Outlook, By Viagra (Sildenafil Citrate) (2021-2030) ($MN)
23 North America Erectile Dysfunction Drugs Market Outlook, By Avanafil (Stendra/Spedra) (2021-2030) ($MN)
24 North America Erectile Dysfunction Drugs Market Outlook, By Cialis (Tadalafil) (2021-2030) ($MN)
25 North America Erectile Dysfunction Drugs Market Outlook, By Helleva (Lodenafil Carbonate) (2021-2030) ($MN)
26 North America Erectile Dysfunction Drugs Market Outlook, By Levitra/Staxyn (Vardenafil) (2021-2030) ($MN)
27 North America Erectile Dysfunction Drugs Market Outlook, By Mvix (Mirodenafil) (2021-2030) ($MN)
28 North America Erectile Dysfunction Drugs Market Outlook, By Vitaros (Alprostadil) (2021-2030) ($MN)
29 North America Erectile Dysfunction Drugs Market Outlook, By Zydena (Udenafil) (2021-2030) ($MN)
30 North America Erectile Dysfunction Drugs Market Outlook, By Other Drug Types (2021-2030) ($MN)
31 North America Erectile Dysfunction Drugs Market Outlook, By Route of Administration (2021-2030) ($MN)
32 North America Erectile Dysfunction Drugs Market Outlook, By Oral Medications (2021-2030) ($MN)
33 North America Erectile Dysfunction Drugs Market Outlook, By Topical Medications (2021-2030) ($MN)
34 North America Erectile Dysfunction Drugs Market Outlook, By Injections (2021-2030) ($MN)
35 North America Erectile Dysfunction Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
36 North America Erectile Dysfunction Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
37 North America Erectile Dysfunction Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
38 North America Erectile Dysfunction Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
39 Europe Erectile Dysfunction Drugs Market Outlook, By Country (2021-2030) ($MN)
40 Europe Erectile Dysfunction Drugs Market Outlook, By Drug Type (2021-2030) ($MN)
41 Europe Erectile Dysfunction Drugs Market Outlook, By Viagra (Sildenafil Citrate) (2021-2030) ($MN)
42 Europe Erectile Dysfunction Drugs Market Outlook, By Avanafil (Stendra/Spedra) (2021-2030) ($MN)
43 Europe Erectile Dysfunction Drugs Market Outlook, By Cialis (Tadalafil) (2021-2030) ($MN)
44 Europe Erectile Dysfunction Drugs Market Outlook, By Helleva (Lodenafil Carbonate) (2021-2030) ($MN)
45 Europe Erectile Dysfunction Drugs Market Outlook, By Levitra/Staxyn (Vardenafil) (2021-2030) ($MN)
46 Europe Erectile Dysfunction Drugs Market Outlook, By Mvix (Mirodenafil) (2021-2030) ($MN)
47 Europe Erectile Dysfunction Drugs Market Outlook, By Vitaros (Alprostadil) (2021-2030) ($MN)
48 Europe Erectile Dysfunction Drugs Market Outlook, By Zydena (Udenafil) (2021-2030) ($MN)
49 Europe Erectile Dysfunction Drugs Market Outlook, By Other Drug Types (2021-2030) ($MN)
50 Europe Erectile Dysfunction Drugs Market Outlook, By Route of Administration (2021-2030) ($MN)
51 Europe Erectile Dysfunction Drugs Market Outlook, By Oral Medications (2021-2030) ($MN)
52 Europe Erectile Dysfunction Drugs Market Outlook, By Topical Medications (2021-2030) ($MN)
53 Europe Erectile Dysfunction Drugs Market Outlook, By Injections (2021-2030) ($MN)
54 Europe Erectile Dysfunction Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
55 Europe Erectile Dysfunction Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
56 Europe Erectile Dysfunction Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
57 Europe Erectile Dysfunction Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
58 Asia Pacific Erectile Dysfunction Drugs Market Outlook, By Country (2021-2030) ($MN)
59 Asia Pacific Erectile Dysfunction Drugs Market Outlook, By Drug Type (2021-2030) ($MN)
60 Asia Pacific Erectile Dysfunction Drugs Market Outlook, By Viagra (Sildenafil Citrate) (2021-2030) ($MN)
61 Asia Pacific Erectile Dysfunction Drugs Market Outlook, By Avanafil (Stendra/Spedra) (2021-2030) ($MN)
62 Asia Pacific Erectile Dysfunction Drugs Market Outlook, By Cialis (Tadalafil) (2021-2030) ($MN)
63 Asia Pacific Erectile Dysfunction Drugs Market Outlook, By Helleva (Lodenafil Carbonate) (2021-2030) ($MN)
64 Asia Pacific Erectile Dysfunction Drugs Market Outlook, By Levitra/Staxyn (Vardenafil) (2021-2030) ($MN)
65 Asia Pacific Erectile Dysfunction Drugs Market Outlook, By Mvix (Mirodenafil) (2021-2030) ($MN)
66 Asia Pacific Erectile Dysfunction Drugs Market Outlook, By Vitaros (Alprostadil) (2021-2030) ($MN)
67 Asia Pacific Erectile Dysfunction Drugs Market Outlook, By Zydena (Udenafil) (2021-2030) ($MN)
68 Asia Pacific Erectile Dysfunction Drugs Market Outlook, By Other Drug Types (2021-2030) ($MN)
69 Asia Pacific Erectile Dysfunction Drugs Market Outlook, By Route of Administration (2021-2030) ($MN)
70 Asia Pacific Erectile Dysfunction Drugs Market Outlook, By Oral Medications (2021-2030) ($MN)
71 Asia Pacific Erectile Dysfunction Drugs Market Outlook, By Topical Medications (2021-2030) ($MN)
72 Asia Pacific Erectile Dysfunction Drugs Market Outlook, By Injections (2021-2030) ($MN)
73 Asia Pacific Erectile Dysfunction Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
74 Asia Pacific Erectile Dysfunction Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
75 Asia Pacific Erectile Dysfunction Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
76 Asia Pacific Erectile Dysfunction Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
77 South America Erectile Dysfunction Drugs Market Outlook, By Country (2021-2030) ($MN)
78 South America Erectile Dysfunction Drugs Market Outlook, By Drug Type (2021-2030) ($MN)
79 South America Erectile Dysfunction Drugs Market Outlook, By Viagra (Sildenafil Citrate) (2021-2030) ($MN)
80 South America Erectile Dysfunction Drugs Market Outlook, By Avanafil (Stendra/Spedra) (2021-2030) ($MN)
81 South America Erectile Dysfunction Drugs Market Outlook, By Cialis (Tadalafil) (2021-2030) ($MN)
82 South America Erectile Dysfunction Drugs Market Outlook, By Helleva (Lodenafil Carbonate) (2021-2030) ($MN)
83 South America Erectile Dysfunction Drugs Market Outlook, By Levitra/Staxyn (Vardenafil) (2021-2030) ($MN)
84 South America Erectile Dysfunction Drugs Market Outlook, By Mvix (Mirodenafil) (2021-2030) ($MN)
85 South America Erectile Dysfunction Drugs Market Outlook, By Vitaros (Alprostadil) (2021-2030) ($MN)
86 South America Erectile Dysfunction Drugs Market Outlook, By Zydena (Udenafil) (2021-2030) ($MN)
87 South America Erectile Dysfunction Drugs Market Outlook, By Other Drug Types (2021-2030) ($MN)
88 South America Erectile Dysfunction Drugs Market Outlook, By Route of Administration (2021-2030) ($MN)
89 South America Erectile Dysfunction Drugs Market Outlook, By Oral Medications (2021-2030) ($MN)
90 South America Erectile Dysfunction Drugs Market Outlook, By Topical Medications (2021-2030) ($MN)
91 South America Erectile Dysfunction Drugs Market Outlook, By Injections (2021-2030) ($MN)
92 South America Erectile Dysfunction Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
93 South America Erectile Dysfunction Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
94 South America Erectile Dysfunction Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
95 South America Erectile Dysfunction Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
96 Middle East & Africa Erectile Dysfunction Drugs Market Outlook, By Country (2021-2030) ($MN)
97 Middle East & Africa Erectile Dysfunction Drugs Market Outlook, By Drug Type (2021-2030) ($MN)
98 Middle East & Africa Erectile Dysfunction Drugs Market Outlook, By Viagra (Sildenafil Citrate) (2021-2030) ($MN)
99 Middle East & Africa Erectile Dysfunction Drugs Market Outlook, By Avanafil (Stendra/Spedra) (2021-2030) ($MN)
100 Middle East & Africa Erectile Dysfunction Drugs Market Outlook, By Cialis (Tadalafil) (2021-2030) ($MN)
101 Middle East & Africa Erectile Dysfunction Drugs Market Outlook, By Helleva (Lodenafil Carbonate) (2021-2030) ($MN)
102 Middle East & Africa Erectile Dysfunction Drugs Market Outlook, By Levitra/Staxyn (Vardenafil) (2021-2030) ($MN)
103 Middle East & Africa Erectile Dysfunction Drugs Market Outlook, By Mvix (Mirodenafil) (2021-2030) ($MN)
104 Middle East & Africa Erectile Dysfunction Drugs Market Outlook, By Vitaros (Alprostadil) (2021-2030) ($MN)
105 Middle East & Africa Erectile Dysfunction Drugs Market Outlook, By Zydena (Udenafil) (2021-2030) ($MN)
106 Middle East & Africa Erectile Dysfunction Drugs Market Outlook, By Other Drug Types (2021-2030) ($MN)
107 Middle East & Africa Erectile Dysfunction Drugs Market Outlook, By Route of Administration (2021-2030) ($MN)
108 Middle East & Africa Erectile Dysfunction Drugs Market Outlook, By Oral Medications (2021-2030) ($MN)
109 Middle East & Africa Erectile Dysfunction Drugs Market Outlook, By Topical Medications (2021-2030) ($MN)
110 Middle East & Africa Erectile Dysfunction Drugs Market Outlook, By Injections (2021-2030) ($MN)
111 Middle East & Africa Erectile Dysfunction Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
112 Middle East & Africa Erectile Dysfunction Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
113 Middle East & Africa Erectile Dysfunction Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
114 Middle East & Africa Erectile Dysfunction Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
List of Figures
RESEARCH METHODOLOGY
We at ‘Stratistics’ opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.
Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.
Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.
Data Mining
The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.
Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.
Data Analysis
From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:
- Product Lifecycle Analysis
- Competitor analysis
- Risk analysis
- Porters Analysis
- PESTEL Analysis
- SWOT Analysis
The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.
Data Validation
The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.
We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.
The data validation involves the primary research from the industry experts belonging to:
- Leading Companies
- Suppliers & Distributors
- Manufacturers
- Consumers
- Industry/Strategic Consultants
Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.
For more details about research methodology, kindly write to us at info@strategymrc.com
Frequently Asked Questions
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
We have 3 different licensing options available in electronic format.
- Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
- 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
- Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment.
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.
Request Customization
We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.
WHY CHOOSE US ?
Assured Quality
Best in class reports with high standard of research integrity
24X7 Research Support
Continuous support to ensure the best customer experience.
Free Customization
Adding more values to your product of interest.
Safe & Secure Access
Providing a secured environment for all online transactions.
Trusted by 600+ Brands
Serving the most reputed brands across the world.
